Aurobindo Pharma, Cadila Healthcare and Serum Institute are readying their vaccine candidates.
For India Inc, latest GDP figures signal a turnaround.
A recent report has suggested that future patent expires in the cardiac and anti-diabetes space would form a good opportunity for smaller firms, given their franchise in these segments.
Beside the defence forces in India, the start-up has shipped around 350,000 units to 12 countries -- the United Kingdom, France, Poland, Bangladesh, Saudi Arabia, the UAE, Kenya, South Africa, Romania, Indonesia, Qatar and Oman.
At present, there is no direct air connectivity between India and Myanmar.
One reason Japan is betting highly on Indian pharma is that these companies have strong cash flows, low leverage and high debt capacity for medium to large sized acquisitions.
As many as 24 special economic zone (SEZ) developers including Dr Reddy's Lab and Tata Consultancy Services have sought more time from the government to execute their projects.
Govt bans brands with annual sales worth Rs 3,728 crore.
This is to take head on big American pharmaceutical giants, which in the recent past had launched a strong anti-India campaign against efforts of such companies to provide affordable health care not only to people in India, but also in the third world countries.
The store that made Prime Minister Narendra Modi's monogrammed suit in Ahmedabad are now flooded with requests from people who want similar attire, finds out Sabu Cherian
Markets surged in late trades to snap five-day losing streak led by bank shares.
The category is expected to cross Rs 38,400 crore by 2020.
Under MRA, Japan is to recognise Indian medical degrees and treat the country's doctors and other medical personnel on par with its own.
A glance back at some of the important ups and down Indian Inc faced in 2018.
Armed with green nod and fund infusion, Gujarat govt getting ready to issue tenders to build infrastructure at the mega investment region
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances